Relationships between coagulation factors and thrombin generation in a general population with arterial and venous disease background.
Arterial thrombosis
Coagulation factors
Thrombin generation
Venous thrombosis
Journal
Thrombosis journal
ISSN: 1477-9560
Titre abrégé: Thromb J
Pays: England
ID NLM: 101170542
Informations de publication
Date de publication:
08 Jun 2022
08 Jun 2022
Historique:
received:
27
01
2022
accepted:
24
05
2022
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
The current study aims to identify the relationships between coagulation factors and plasma thrombin generation in a large population-based study by comparing individuals with a history of arterial or venous thrombosis to cardiovascular healthy individuals. This study comprised 502 individuals with a history of arterial disease, 195 with history of venous thrombosis and 1402 cardiovascular healthy individuals (reference group) from the population-based Gutenberg Health Study (GHS). Calibrated Automated Thrombography was assessed and coagulation factors were measured by means of BCS XP Systems. To assess the biochemical determinants of TG variables, a multiple linear regression analysis, adjusted for age, sex and antithrombotic therapy, was conducted. The lag time, the time to form the first thrombin, was mainly positively associated with the natural coagulant and anti-coagulant factors in the reference group, i.e. higher factors result in a longer lag time. The same determinants were negative for individuals with a history of arterial or venous thrombosis, with a 10 times higher effect size. Endogenous thrombin potential, or area under the curve, was predominantly positively determined by factor II, VIII, X and IX in all groups. However, the effect sizes of the reported associations were 4 times higher for the arterial and venous disease groups in comparison to the reference group. This large-scale analysis demonstrated a stronger effect of the coagulant and natural anti-coagulant factors on the thrombin potential in individuals with a history of arterial or venous thrombosis as compared to healthy individuals, which implicates sustained alterations in the plasma coagulome in subjects with a history of thrombotic vascular disease, despite intake of antithrombotic therapy.
Sections du résumé
BACKGROUND
BACKGROUND
The current study aims to identify the relationships between coagulation factors and plasma thrombin generation in a large population-based study by comparing individuals with a history of arterial or venous thrombosis to cardiovascular healthy individuals.
METHODS
METHODS
This study comprised 502 individuals with a history of arterial disease, 195 with history of venous thrombosis and 1402 cardiovascular healthy individuals (reference group) from the population-based Gutenberg Health Study (GHS). Calibrated Automated Thrombography was assessed and coagulation factors were measured by means of BCS XP Systems. To assess the biochemical determinants of TG variables, a multiple linear regression analysis, adjusted for age, sex and antithrombotic therapy, was conducted.
RESULTS
RESULTS
The lag time, the time to form the first thrombin, was mainly positively associated with the natural coagulant and anti-coagulant factors in the reference group, i.e. higher factors result in a longer lag time. The same determinants were negative for individuals with a history of arterial or venous thrombosis, with a 10 times higher effect size. Endogenous thrombin potential, or area under the curve, was predominantly positively determined by factor II, VIII, X and IX in all groups. However, the effect sizes of the reported associations were 4 times higher for the arterial and venous disease groups in comparison to the reference group.
CONCLUSION
CONCLUSIONS
This large-scale analysis demonstrated a stronger effect of the coagulant and natural anti-coagulant factors on the thrombin potential in individuals with a history of arterial or venous thrombosis as compared to healthy individuals, which implicates sustained alterations in the plasma coagulome in subjects with a history of thrombotic vascular disease, despite intake of antithrombotic therapy.
Identifiants
pubmed: 35676710
doi: 10.1186/s12959-022-00392-0
pii: 10.1186/s12959-022-00392-0
pmc: PMC9175351
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32Informations de copyright
© 2022. The Author(s).
Références
Hamostaseologie. 2019 Jun;39(2):152-163
pubmed: 30722070
Thromb Haemost. 2000 Jan;83(1):5-9
pubmed: 10669145
Thromb Haemost. 2008 Aug;100(2):240-5
pubmed: 18690343
Thromb Haemost. 2000 Nov;84(5):747-51
pubmed: 11127849
Bioessays. 2003 Dec;25(12):1220-8
pubmed: 14635257
J Thromb Haemost. 2011 Mar;9(3):450-6
pubmed: 21143375
N Engl J Med. 2003 Apr 10;348(15):1435-41
pubmed: 12686699
Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53
pubmed: 13679651
Int J Cardiol. 2015;187:166-74
pubmed: 25828346
Circ Cardiovasc Imaging. 2010 Sep;3(5):604-13
pubmed: 20643817
Haematologica. 2019 Dec 05;105(9):2327-2334
pubmed: 33054057
Br J Haematol. 1997 Jun;97(4):785-97
pubmed: 9217177
Thromb Haemost. 2002 Oct;88(4):576-82
pubmed: 12362226
Thromb Haemost. 2014 Nov;112(5):860-7
pubmed: 25231258
J Thromb Haemost. 2012 Dec;10(12):2544-54
pubmed: 23020632
Dtsch Arztebl Int. 2012 Apr;109(16):293-9
pubmed: 22577476
PLoS One. 2016 Jul 15;11(7):e0158355
pubmed: 27419389
J Thromb Haemost. 2005 Aug;3(8):1894-904
pubmed: 16102057
J Thromb Haemost. 2008 Jan;6(1):125-31
pubmed: 17988231
PLoS One. 2013 Jun 24;8(6):e66977
pubmed: 23826181
Thromb Haemost. 2002 Feb;87(2):300-5
pubmed: 11858491
J Thromb Haemost. 2003 May;1(5):907-14
pubmed: 12871355
Haemophilia. 2018 Nov;24(6):995-1001
pubmed: 29957846
Br J Haematol. 2008 Mar;140(5):488-95
pubmed: 18275426
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1445-51
pubmed: 21454811
Blood. 2008 Nov 15;112(10):4061-8
pubmed: 18768782
Blood. 2000 Jun 15;95(12):3678-82
pubmed: 10845896
Blood. 1996 Nov 15;88(10):3698-703
pubmed: 8916933
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Jun;55(6-7):824-9
pubmed: 22736163
Thromb Res. 2012 Mar;129(3):367-70
pubmed: 22079443